Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness in Chronic Kidney Disease
Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness
Overview:
In this webinar, Katie will review how optical imaging works and provide some common examples of how it’s used within preclinical research. She will then introduce the Newton 7.0 FT500, an optical imaging system manufactured by Vilber that includes bioluminescence, fluorescence, and 3D tomography capabilities. She will end the webinar by going through some of the most common questions/considerations that come up for those looking to add optical imaging capabilities to their lab.
The Newton 7.0 is a highly sensitive optical imaging system dedicated to preclinical imaging of small animals in vivo, and may also be used on a variety of in vitro and ex vivo samples. It combines the best optics and animal handling features for high-quality image data and quantification. The Newton 7.0 system is capable of bioluminescence, fluorescence as well as 3D tomographic imaging.
The system is:
Whether you are just exploring the idea of adding optical capabilities to your lab or you’ve been imaging for years, you won’t want to miss the opportunity to learn about this cool new technology and ask questions about your specific research applications and study design.
Learning objectives:
In collaboration with The Keenan Research Center for Biomedical Science, Toronto
Publication Highlight: Activation of the IKK2/NF-κB pathway in VSMCs inhibits calcified vascular stiffness
Application Note: Bioprinting 3D Multi-cellular Cartilage Spheroids Using Laser-Assisted Technology View Paper Here
Publication Highlight: Single High-Dose Erythropoietin Disrupts Bone Homeostasis via Osteoclastogenic Pathways View Paper
Publication Highlight: Long-Term Optical Imaging Reveals Bone Marrow Clearance and Extramedullary Escape in
Publication Highlight: Overexpression of IL-32γ inhibits skin cancer formation through suppression of NF-κB
Publication Highlight: The role of phosphodiesterase 5 inhibitors in attenuating obesity-induced metabolic disorders